These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 38525480)

  • 1. New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists.
    Peng A; Chai J; Wu H; Bai B; Yang H; He W; Zhao Y
    Neuropsychiatr Dis Treat; 2024; 20():607-620. PubMed ID: 38525480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.
    Okubo R; Okada M; Motomura E
    Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histamine H
    Mahmood D
    Int J Health Sci (Qassim); 2016 Oct; 10(4):564-575. PubMed ID: 27833522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
    Reynolds GP
    J Psychopharmacol; 2021 Sep; 35(9):1030-1036. PubMed ID: 34256637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability.
    Amato D; Vernon AC; Papaleo F
    Neurosci Biobehav Rev; 2018 Feb; 85():146-159. PubMed ID: 28970021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 Feb; 57(2):7-11. PubMed ID: 30703220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S; Yoshida S; Okuyama S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
    Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
    Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antipsychotics with no dopamine receptor blockade; promise or hype?].
    Vinkers CH
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
    Seeman P
    CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics.
    Meltzer HY
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):2S-3S. PubMed ID: 7730497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.